CA-4948 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), a reversible kinase inhibitor that is orally active, from the patent WO2015104688 A1 (Example 1). It can be used to study cancer and inflammatory diseases.

 

Brand: BCM

 

Target: IRAK

 

Signaling Pathways: Immunology/Inflammation; NF-κB

 

In Vivo: CA-4948 is a selective and potent IRAK4 inhibitor that can be used as a therapeutic agent for blood cancers with dysregulated TLR/MYD88/IRAK4 signaling. CA-4948 exhibits favorable DMPK properties, oral bioavailability, and is well tolerated in mice. In addition, CA-4948 was previously shown to show dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models.

 

Melting Point: >294°C (dec.)

 

pKa: 10.41±0.43(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS07

 

Isomeric SMILES: C1COCCN1C2=NC3=C(O2)C=C(C=N3)NC(=O)C4=CC=CC(=N4)C5=CN=C(C=C5)N  

 

InChIKey: RWIMETUXCNDSLE-UHFFFAOYSA-N  

 

InChI: InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29) 

 

Attribute
[Chem Name]	6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide
[Synonym]	CA-4948; IRAK4-IN-2
[CAS No.]	1801343-74-7
[MDL No.]	MFCD31619276
[Formula]	C21H19N7O3
[Molecular]	417.42
[Form]	Pale Yellow to Brown Solid
[Storage]	Keep in dark place. Sealed in dry, 2-8°C

Goods Tag